navdx logo white

The first and only clinically validated circulating TTMV® DNA blood test that aids in the detection of HPV-driven cancer.

A highly accurate, reliable blood test.

NavDx is the first and only clinically validated circulating tumor-tissue–modified HPV (TTMV®) DNA blood test that aids in the detection of HPV-driven cancer.

 

NavDx uses proprietary technology to quantify fragments of circulating TTMV HPV DNA, a unique HPV-driven cancer biomarker that cancer cells shed into the blood. This highly accurate blood test reliably uncovers the presence of HPV+ head and neck cancer across the care continuum.¹˒²˒³

scientist with dna

Clinical utility has been validated in multiple studies for head and neck cancer,¹˒³ and proven in real-world practice.³

Distinguishes TTMV HPV DNA from non-cancerous sources of HPV DNA².

NavDx has ≥95% positive and negative predictive values (PPV and NPV) for active, HPV-driven malignancy¹˒³.

Quicker diagnoses. Improved outcomes.

NavDx lets you optimize clinical management of HPV-driven cancer by:

  • Accurately assessing treatment response
  • Identifying the presence of post-treatment molecular residual disease
  • Conveniently monitoring for recurrence.¹˒³

The easy-to-interpret, actionable NavDx test report helps inform clinical decisions, enabling physicians to treat earlier, which may result in improved outcomes.

doctor with patient

This innovative and accessible blood test for HPV+ cancer helps inform clinical decisions, enabling physicians to intervene earlier, which may result in improved outcomes.¹˒³

Get Started with NavDx


nav dx bottom